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ABSTRACT OF THESIS

GASTROINTESTINAL BLEEDING EVENTS AND STATIN USE:
A LARGE PROPENSITY SCORE-MATCHED
RETROSPECTIVE COHORT STUDY
Literature is conflicting regarding the association between statin use and
gastrointestinal (GI) bleeding. This study sought to determine whether there is an
association between statin use and GI bleeding by comparing incidence of
gastrointestinal events between statin users and an active comparator group.
Data was obtained from a large administrative claims database composed of subjects
enrolled in a selection of insurance plans throughout the United States from 2009-2014.
New statin users (exposed) and thyroid medication users (active comparator, unexposed)
were followed from the baseline period (one year prior to medication initiation) until first
event, discontinuation, or disenrollment. Subjects were matched using a propensity score
based on demographics, comorbidities, healthcare utilization, and medication use. Odds
of gastrointestinal events, including GIH, gastroduodenal (GD) ulcer, and
gastritis/duodenitis were compared between groups.
The final analysis included 1,442,954 statin users matched using a 1:1 algorithm with
replacement to thyroid medication users. Frequency of GIH in the unexposed group was
0.56±0.01% and frequency in the low, moderate, and high-intensity statin users group
was 0.81±0.03%, 0.91±0.02%, and 0.90±0.05% respectively (p<0.002). Statin users had
1.81 times the rate of GIH compared to the active comparator group (HR 1.81; 95%
confidence interval (CI) 1.76-1.86). Hazard ratios for GD ulcer and gastritis/duodenitis
events were 1.13 (CI 0.618-2.05) and 1.19 (CI 0.796-1.80) respectively.
Practitioners should consider these trends when prescribing statins in patients at highrisk of bleeding. Additional research is needed to verify the association between statins
and GIH.

KEYWORDS: gastrointestinal hemorrhage, statins, HMG-coA reductase inhibitors,
propensity score matching, time-to-event analysis
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SECTION ONE: INTRODUCTION
Statin Use
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins)
are widely utilized, with 28% of Americans having used a statin in the last 30 days.
Among Americans with cardiovascular disease utilization is even higher, approximating
70% (based on data from 2012).1 Both atorvastatin and simvastatin were in the top ten
medicines by prescription, equating to nearly 154 million prescriptions per month in
2014.2
As with most commonly utilized medications, statins are generally considered safe
and effective, with the most common adverse effects including mild diarrhea, limb and
musculoskeletal pain, and elevated serum transaminases (2-20% incidence). Serious
adverse effects such as rhabdomyolysis and liver damage have been reported to occur at
<2% frequency.3 In addition to these rare adverse effects, bleeding events such as
epistaxis and hematuria have also been reported in post-marketing surveillance.
Statins are primarily used to treat hypercholesterolemia, due to their inhibition of
HMG-coA reductase causing decreased cholesterol synthesis in the liver. Outside of
lipid-lowering effects, statins also result in endothelial protection, plaque stabilization,
and antithrombotic and antiplatelet effects in the cardiovascular system through reduced
mevalonate production, which results in decreased activation of small GTP-ases Ras and
Rho (see Figure 1.1). Due to these cardiovascular protective effects, statins are also
indicated for both primary and secondary prevention of atherosclerotic cardiovascular
disease (ASCVD). Patients with ASCVD are often on other antiplatelet or anticoagulant
medications due to common comorbidities such as myocardial infarction, stroke, and
thromboses.
If statins exert a cardiovascular protective effect through the cholesterol synthesis
pathway, then it is unlikely they would have additional bleeding adverse effects.
However, there is evidence that suggests statins have anticoagulant and antiplatelet
activity independent of their lipid-lowering effects. This may result in an increased risk of
bleeding events, which is especially concerning given that a relatively high proportion of
statin users are also on anticoagulants.
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Figure 1.1-Statin Mechanism of Action

Proposed Mechanistic Explanations
Research into the effect of statins on both the coagulation and the platelet cascades
suggests that statins may potentially have effects on blood clotting, and thus on bleeding
events, outside of the cholesterol lowering pathway. Evidence suggests statins decrease
tissue factor (TF) expression, modify various coagulation factors, and decrease the
number and activation of platelets.
Tissue factor is a transmembrane receptor expressed on many cells that surround
blood vessels.4 Its binding with Factor VIIa is necessary to initiate the extrinsic pathway
of the coagulation cascade (see Figure 1.2). Colli and colleagues found that lipophilic
statins (fluvastatin and simvastatin) dose-dependently decreased TF expression by
preventing an inducer from binding to the TF promoter. This effect was reversed by
adding mevalonate, which suggests that the TF expression inhibition may be related to
statins’ effect on the cholesterol synthesis pathway.5 Similar results were found in
another study, wherein investigators demonstrated that cerivastatin also reduced TF
expression.6 Ferro et al. was able to verify that this statin-induced reduced TF expression
does in fact decrease the rate of thrombin generation, and thus the rate of clot formation.7
The inability to adequately form clots may result in a higher likelihood of bleeding.
In addition to their effect on tissue factor expression, there is also evidence to suggest
statins affect other components of the coagulation cascade. Simvastatin has been shown
4

to decrease the rate of prothrombin (factor II) activation, factor Va generation, factor XIII
activation, and fibrin formation from fibrinogen, as well as increase the rate of factor Va
inactivation.8 These changes result in the depression of thrombus formation, but there is
also evidence that statins can increase the rate of thrombus degradation. Dangas et al.
investigated the effect of statins on the thrombolytic pathway and found that pravastatin
decreased the amount of plasminogen activator inhibitor-1 and the rate of thrombus
formation regardless of changes in cholesterol level.9
The platelet cascade has also been implicated as a mechanism for statin-induced antithrombotic activity. Lovastatin has been shown to dose-dependently reduce platelet
aggregation (mediated through both collagen and thrombin) and to dose-dependently
induce platelet apoptosis.10 Another study demonstrated that rosuvastatin impacted the
platelet cascade in a dose-dependent manner by inhibiting platelet recruitment.11 Further
evidence of statins’ effect on platelets involves a von Willebrand factor (vWF) cleaving
protease, ADAMTS13, which is implicated as the main cause of thrombotic
thrombocytopenia (TTP). Shen et al. found that simvastatin upregulated ADAMTS13
expression, leading to increased cleavage of vWF, and thus decreased platelet
activation.12

Figure 1.2-Coagulation and Platelet Cascades
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Existing Clinical Correlations
While there are numerous hypotheses for a possible mechanism for statin-induced
bleeding events, studies investigating the clinical correlation of statin use and bleeding
have not yielded consistent results. These studies have largely investigated either GI
bleeds or intracerebral hemorrhages (ICH), as case studies have suggested possible risks
in these areas. To date, some studies have found a decreased risk of bleeding associated
with statin use, others suggest an increased risk of bleeding, while other researchers were
unable to find any association at all (see Table 1.1).
Decreased Risk
Of the studies that found statin use was associated with a lower risk of bleeding,
one nested case-control study of warfarin patients with atrial fibrillation found that
statin use of one year or more was associated with a lower risk of GI bleeding.
However, investigators did not find a similar association with recent statin use or
statin use of any duration.13 In a subgroup analysis of the OPUS-TIMI 16 trial,
investigators found that statin users had lower rates of in-hospital GI bleeding than
non-users.14 Another study in rats found that simvastatin decreased both gastric
acidity and the size of indomethacin-induced ulcers.15 A retrospective analysis
investigating the predictors of ICH found that statins were actually associated with a
decreased ICH volume.16
Increased Risk
In contrast, there have also been studies that have reported an increased risk of
bleeding associated with statin use. There have been reported cases of gastric
ulceration,17 thrombocytopenia (TCP),10,18–22 thrombotic thrombocytopenic purpura
(TTP),23–25 and hemorrhagic cystitis26 associated with recent initiation and continued
use of statins, which have resolved after discontinuation. Varying levels of TCP
(mild, moderate, and severe) possibly associated with statin use have been reported in
the literature. When it happens, severe events are more commonly reported. Of the
twelve case reports associating statins with bleeding, two reported TTP within 24
hours of beginning a new simvastatin therapy, which improved rapidly after drug
discontinuation.24,25 Five reports (two of TCP purpura, two of TCP, and one of

6

hemorrhagic cystitis) claimed that the adverse reaction took place within one week of
statin initiation and again resolved quickly after discontinuation.18–20,23,26 In one case,
severe TCP occurred after switching from one atorvastatin manufacturer to a new
generic manufacturer and hadn’t occurred with previous simvastatin therapy. Again,
this suggests that different statins may have different bleeding risks. Three reports
posit a causal relationship between statin use, TCP, and gastric ulceration that
occurred after a few months on statin therapy, but that resolved quickly upon
switching to simvastatin (from atorvastatin) or discontinuing satin therapy.17,21,27
Finally, one report claimed that a woman experienced TCP purpura after 3 years on a
steady dose of simvastatin without any known drug interactions, which improved
after 2 weeks of stopping the drug.22 While the report makes a convincing argument
that there are no other possible causes, the fact that the patient had been on therapy
for so long makes it seem less likely that this report demonstrates a causal
relationship. There are also incidental findings from randomized controlled trials that
suggest statin users have higher rates of thrombocytopenia and hemorrhage than nonusers.28,29 Furthermore, two studies in rats showed larger indomethacin-induced
gastric ulcers in simvastatin, atorvastatin, and rosuvastatin treated rats, which is
contrary to the previously discussed study in rats.30,31 Outside of GI bleeding and
ulceration, there have been numerous studies suggesting an increased risk of ICH in
statin users. These include a secondary analysis of the large SPARCL trial, a metaanalysis of seven randomized controlled trials, and two retrospective studies.32–35 This
finding that not all statins equally affect bleeding risk is not unique to this study.
Some studies have suggested that in addition to a dose-dependent effect, there may
also be a difference amongst statins based on lipophilicity (suggesting that the
mechanism is gene-mediated), while others hypothesized a chemical structure
relationship (finding more synthetic statins have a higher risk). There is also a study
implicating certain ApoE genotypes as an important factor in the increased risk of
ICH associated with statin use.36
No Association
While there have been studies that have found an increased risk of bleeding and
studies that found a decreased risk of bleeding with statin use, other have investigated
7

the correlation and found no association. For example, one case-control study found
no association between statin use (current, recent, or past) and upper GI bleeds, while
another investigated patients treated with a thrombolytic and a statin and also found
no correlation in the risk for subsequent bleeds.37,38 A meta-analysis of 31
randomized controlled trials of statin therapy that reported ICH found that active
statin therapy was not associated with a significant increase in ICH.39 Interestingly, a
recent retrospective study that initially found a protective effect of statins on major
bleeds in those treated with anticoagulants later found that this protective effect
disappeared when users were stratified by age and duration of statin use.40 A second
retrospective analysis, which was performed with propensity score matching, also
found no association.41

Overall, investigations into the clinical correlation between statin use and
gastrointestinal bleeding have given mixed results, and studies are mostly small and/or
post-hoc.

Table 1.1-Summary of Clinical Correlations
Study Type
Subgroup analysis
Case-control
Chart review
In vitro
Subgroup analysis
RCT
RCT
In vitro
Meta-analysis
Chart review
Case-control
In vitro
Case-control
Cohort
Chart review
Case-control
Meta-analysis
Cohort

Population

Size (n)
Decreased Bleeding Risk
Acute coronary syndrome
10 288
A. fib., on warfarin
79 207
ICH cases
139
Rats
18
Increased Bleeding Risk
History of stroke or TIA
4 731
Hypercholesterolemic patients 2 195
Acute myocardial infarction
2 082
Rats
48
High-dose statin users
31 099
IV thrombolytic users
1 446
Warfarin users
353 489
Rats
150
Hypercholesterolemic patients 558
No Bleeding Association
Statin users
6 342
Alteplase-treated patients
119
Serious upper GI bleed
3 652
Statin users
31 099
A. fib., on anticoagulants
8 188

Outcome

Author

Inpatient GI bleeds
Upper GI or ICH
ICH
Gastric ulcer size

Atar
Douketis
Falcone
Tariq

Hemorrhagic stroke
TCP
TCP, hemorrhage
Gastric ulcer size
ICH
ICH
GI bleeding
Gastric ulcer size
ICH

Huisa
Miserez
Nikolsky
Özbakis
Pandit
Scheitz
Schelleman
Timoshin
Woo

GI hemorrhage
ICH
GI bleed
ICH
Minor/major bleed

Badillo
Geng
Gulmez
McKinney
van Rein

A. fib = atrial fibrillation; GI = gastrointestinal; ICH = intracerebral hemorrhage; RCT = randomized controlled trial; TIA =
transient ischemic stroke
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Clinical Relevance
Upper GIHs are most often caused by an acidic peptic disease (such as gastric and
duodenal ulcers, as well as gastritis), followed by variceal bleeding and erosive diseases.
Diverticulosis and angiodysplasia are the most common causes of lower GIH.42 However,
if it is the case that statins are in some way associated with an increased risk of GI
bleeding events, this could have a significant impact on the healthcare system. Studies
estimate that the incidence of upper GIH is anywhere from 40 to 150 per 100 000 cases
annually,43 while lower GIH occurs around 20 to 30 per 100 000 cases annually.44
Furthermore, a 2010 study found that patients who experienced upper GIH had higher
healthcare utilization and costs in the subsequent 12 months compared to those who did
not.45 This finding remained significant even after excluding initial hospitalization costs,
which were on average $11,228 for the upper GIH cohort compared to $3,652 for the
general population cohort.
Furthermore, there is a significant proportion of statin users who are already at a
higher risk of bleeding due to patients being concurrently treated with antiplatelets and
anticoagulants. Finding that statins are associated with an increased risk of GI bleeding
could lead clinicians to weigh the risk to benefit ratio of prescribing this class of
medication in select groups of patients. The purpose of this study was to investigate
whether statin use is associated with GI bleeding events by comparing GI bleeding event
incidence between statin users (exposed) and an active comparator (unexposed) group.
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SECTION TWO: METHODS
Study Population
This study was a retrospective cohort analysis of subjects enrolled in health plans
between 2009-2014 gathered from the Truven Health MarketScan® Research Database.46
The database includes de-identified medical and prescription claims from nearly 350
private payers. Because this data is de-identified and anonymous, it does not meet the
federal definition of “human subjects research” and thus is IRB exempt.47
Subjects aged 30-65 years at the time of first statin or thyroid hormone medication fill
(index date) as documented by private insurers in the database were analyzed. To ensure
the analysis included only new users and to avoid data contamination by users of both
study medications, 12 months of continuous enrollment (allowing a 30-day gap in
coverage) without a documented fill for either study medication was required (baseline
period). Follow-up began on the index date and continued until first GI bleeding event
(GIH, ulcer, gastritis, or duodenitis). Censoring occurred at treatment discontinuation (90
days after completion of the last study medication), disenrollment, or the end of the data,
whichever came first. A flow diagram depicting subject selection is visualized in Figure
2.1-Subject Selection Process Data were retrieved using SAS Enterprise Guide software,
Version 7.1 of the SAS System for Windows.48
Figure 2.1-Subject Selection Process
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Exposure and Outcomes
This study employed an active comparator design. As such, two treatment groups
were identified using GPI codes: statin users (exposed) and thyroid medication users
(unexposed) (see Appendix C). Exposed individuals were defined as those with a
prescription claim for a statin. Subjects were followed until first GI bleeding event
(whether GIH, ulcer, gastritis, or duodenitis) and were censored at treatment
discontinuation (defined as 90 days after the last supply of medication was exhausted) or
disenrollment from the database.
The primary outcome in this study was GIH, although secondary outcomes of
gastroduodenal ulcer and gastritis or duodenitis were also documented. GI bleeding
events were identified from the first three diagnosis codes of both in- and outpatient visits
documented in the database. These conditions were defined using AHRQ-CCS categories
153, 139, 140, 70, and 76 respectively. GIH was defined as bleeding in any segment of
the GI tract from the esophagus to the rectum. GIH diagnosis codes included bleeds of
any cause.
Outcome events were defined as an event that occurred between the index fill and 90
days after the last supply of medication was exhausted.

Confounders
Subject characteristics during the one year prior to treatment initiation (the baseline
period) for the included subjects were identified from MarketScan. These variables were
selected based on literature in the field, factors that might influence the propensity to be
initiated on statin therapy, as well as factors that might influence the propensity to
experience a GI bleeding event. In addition to age and sex, several possible confounders
were included in the analysis.
Disease burden was determined using both the Charlson Comorbidity Index score and
its individual components (AIDS, ulcer, congestive heart failure, cardiovascular disease,
dementia, diabetes with and without complications, liver failure with and without
complications, any malignancy, myocardial infarction, paralysis, renal failure, and
rheumatologic diseases).49 Health system utilization was measured using a categorization
of in- and outpatient visits. Inpatient visits were categorized as 0, 1, or ≥ 2, while
11

outpatient visits were categorized as 0-1, 2-4, 5-6, or > 6. Prescription medication use
during baseline was also measured by having one or more claims for the following
medications, which were also used in a similar study41: angiotensin converting enzyme
inhibitors, antiplatelets, antipsychotics, antithrombotics, aspirin, angiotensin receptor
blockers, beta-blockers, bisphosphonates, calcium channel blockers, corticosteroids,
diuretics, diuretics, oral hypoglycemics, proton pump inhibitors, sedatives, selective
serotonin reuptake inhibitors, testosterone, and warfarin. Definitions for each comorbidity
and prescription can be found in Appendix B and Appendix C.

Propensity Score Matching
In this study, a theory-driven approach was used to select which measured baseline
covariates to include in the final propensity score model.50–54 Of 38 measured baseline
characteristics, 5 were associated only with exposure and thus were not included, and 12
were not found to be associated with either exposure or outcome and were also excluded
(see Table 2.1). Liver disease and diabetes severities were combined into one measure
each, as were malignancies and metastases.
Thus, the final propensity score was estimated using a logistic regression that
included 18 baseline covariates: sex, age category, inpatient visits, outpatient visits, CCI
score category, AIDS, any ulcer, congestive heart failure, cerebrovascular disease,
diabetes, liver disease, cancer, renal failure, and use of bisphosphonates, blood thinners,
corticosteroids, NSAIDs, or PPIs.
Balance in the matched cohort was assessed using standardized differences (or
standardized mean difference, SMD). SMD is used to statistically test whether there is a
difference between the two groups. This study defined imbalance between two groups as
the absolute value of the standardized difference > 0.1, as is common in the literature.55

12

Table 2.1-Baseline Covariate Association with Exposure and Outcome
Associated only with
exposure
Myocardial infarction
PVD58
Use of hypoglycemic
Use of non-statin LLA
Use of antipsychotics62

Associated only with
outcome
Any ulcers
Liver disease59
Malignancy61
Metastases
Use of blood thinners
Use of corticosteroids
Use of NSAIDs43,56,58
Use of PPIs

Associated both with
exposure and outcome
Age56
Sex60
Inpatient visits
Outpatient visits
CCI score
AIDS
CHF64,65
Cerebrovascular disease66,67
Diabetes56
Renal failure68–71
Use of bisphosphonates72

Associated with neither
exposure nor outcome
Dementia56,57
Paralysis
Pulmonary disease
Rheumatic disease58
Use of ACEi or ARBs63
Use of beta-blockers
Use of CCBs
Use of diuretics
Use of sedatives
Use of SSRIs
Use of TCAs
Use of testosterone

ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; CCB = calcium channel blocker; CHF =
congestive heart failure; LLA = lipid lowering agents; NSAID = non-steroidal anti-inflammatory drug; PPI = proton pump
inhibitor; PVD = peripheral vascular disease

In this study, matching was completed with the user-created Stata command
-psmatch2-73 using 1:1 nearest-neighbor matching with replacement with a caliper of 0.25
the standard deviation of the propensity score. Replacement was used as is recommended
in the literature when the unexposed group is significantly smaller than the exposed
group.74

Event Analysis
Subjects were followed until first GI bleeding event and were censored at treatment
discontinuation (defined as 90 days after the last supply of medication was exhausted) or
disenrollment. The incidence rate per person-time at risk of GIH, ulcer, and
gastritis/duodenitis was calculated using Poisson regression and was compared between
exposed and unexposed groups, as well as within the exposed group at different doses.
The number needed to harm was calculated both using incidence rate and cumulative
incidence, and a comparison of both values was included in the analysis.
In addition, a Cox proportional hazard model was used to regress exposure status on
outcome occurrence and determine hazard ratios for risk over time. Frequency weights
and a robust variance estimator were used to account for the unexposed subjects used in
multiple matched pairs, which violate the independent observation assumption in Cox
regressions.
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SECTION THREE:

RESULTS

Propensity Score Model
The output of the logistic regression for propensity score estimation is found in Table
3.1. As can be seen in Figure 3.1, the propensity scores tend to be higher in the exposed
group than the active comparator group. Figure 3.2 demonstrates that the distribution of
propensity scores between the exposed and active comparator groups is identical after
matching.

Table 3.1-Propensity Score Model

Sex, female
Age 30-39 yr
40-49 yr
50-59 yr
≥ 60 yr
No Inpatient Visits
1
>1
0-1 Outpatient Visits
2-4 Visits
5-6 Visits
> 6 Visits
CCI Score 0
1
2
3
4
5
≥6
AIDS
Ulcers
Congestive heart failure
Cerebrovascular disease
Diabetes
Liver disease
Cancer
Renal disease
Bisphosphonates
Blood thinners
Corticosteroids
NSAIDs
PPIs
constant

Odds Ratio
0.261

No. obs = 1 929 762
c-statistic = 0.7302
95 % Confidence Interval
0.258
0.263

2.18
3.30
3.36

2.16
3.27
3.32

2.21
3.34
3.40

1.12
1.17

1.11
1.15

1.13
1.18

0.849
0.711
0.611

0.841
0.700
0.602

0.856
0.721
0.619

1.30
1.23
1.17
0.995
0.809
0.506
3.30
0.814
1.15
2.10
1.90
0.452
0.522
1.11
1.23
0.925
0.931
1.15
1.13
2.42

1.29
1.20
1.14
0.951
0.762
0.484
2.98
0.773
1.11
2.05
1.88
0.427
0.510
1.07
1.20
0.906
0.922
1.14
1.12
2.39

1.32
1.25
1.21
1.04
0.859
0.530
3.64
0.858
1.19
2.15
1.93
0.478
0.534
1.15
1.26
0.944
0.939
1.16
1.15
2.45

AIDS = autoimmune deficiency syndrome; CCI = Charlson Comorbidity Index; NSAIDs =
non-steroidal anti-inflammatory drugs; PPIs = proton pump inhibitors
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Figure 3.1-Unmatched Cohort Propensity Score Distribution

Figure 3.2-Matched Cohort Propensity Score Distribution
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In this study, 21,552 active comparator subjects were matched to 1,442,954 exposed
subjects because matching was done with replacement (see Table 3.2). As can be seen in
Table 3.3, the matched cohort designed without replacement had significantly more bias
than the one completed with replacement.

Table 3.2-Matching in Active Comparator Subjects
No. of
Unexposed Subjects
10 702
6 633
2 057
1 078
865
217

Times Used to Match
an Exposed Subject
1-6
7-25
26-60
61-140
141-860
> 860

Cumulative Percent of
Active Comparator Subjects
49.66
80.43
89.98
94.98
98.99
100.00

Table 3.3-Matching Algorithm Comparison

Unmatched
Matched without Replacement
Matched with Replacement

Active
Comparator
Cases Used
486 808
486 808
21 553

Exposed
Cases Used

Mean
Bias*

Median
Bias

1 442 954
486 808
1 442 954

16.1%
6.2%
0.4%

11.0%
4.1%
0.3%

* Bias is defined as the standardized residual (difference in means divided by pooled standard deviation)

Baseline Characteristics
After all inclusion and exclusion criteria were applied, the full unmatched cohort
consisted of 486,808 individuals in the active comparator group and 1,442,954 exposed
individuals. Baseline characteristics for the unmatched cohort can be found in Table 3.4.
. These groups differ on most confounders included in the propensity score model.
Active comparator individuals (thyroid hormone users) were more likely to be female and
younger, have fewer inpatient but more outpatient visits, and have lower CCI scores.
Significantly more statin users had diabetes and cerebrovascular disease (24.9% vs.
12.2% and 5.0% vs. 2.0, respectively), whereas significantly more thyroid hormone users
had liver disease and cancer (0.48% vs. 0.27% and 8.2% vs. 4.1%, respectively). In the
full unmatched cohort, 0.89% of statin users experienced a GIH, compared to 0.80% in
the active comparator (standardized difference -0.01).
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After matching on the propensity score, the exposed and active comparator groups
were much more similar (see Table 3.5). Of note, statin users used the medication for an
average of 279±325 days while active comparators used thyroid hormone for an average
of 326±333 days. Statin users were followed for an average of 252±284 days, and active
comparators were followed for an average of 331±301 days.
When comparing those who experienced the primary outcome to those who did not,
significantly more subjects with the outcome took moderate intensity statins (see
Appendix C for a definition of statin intensities), had more than six outpatient visits, and
used blood thinners, corticosteroids, and PPIs. However, significantly fewer subjects who
experienced the primary outcome had no inpatient visits, had none or one outpatient visit,
and had a CCI score of 0 than those who did experience the outcome. Exact incidence by
outcome group can be found in Appendix E.
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Table 3.4-Unmatched Cohort Baseline Characteristics

Female, n (%)
Age Categories, n (%)
30-39 y.o.
40-49 y.o.
50-59 y.o.
≥ 60 y.o.
Inpatient Visits, n (%)
0
1
>1
Outpatient Visits, n (%)
0-1
2-4
5-6
>6
CCI, n (%)*
0
1
2
3
4
5
≥6
Comorbidities, n (%)
AIDS
Ulcer
Congestive heart failure
Cerebrovascular disease
Diabetes
Liver disease
Cancer
Kidney disease
Medication Usage, n (%)**
Bisphosphonates
Blood thinners***
Corticosteroids
NSAIDs
PPIs

Active Comparator
n=486 808
387 087 (79.52)

Exposed
n=1 442 954
722 564 (50.08)

Standardized
Difference
-0.648
0.342

92 713 (19.05)
132 623 (27.24)
172 734 (35.48)
88 738 (18.23)

108 562 (7.52)
345 783 (23.96)
642 961 (44.56)
345 648 (23.95)

331 991 (68.20)
101 535 (20.86)
53 282 (10.95)

947 453 (65.66)
328 123 (22.74)
167 378 (11.60)

268 932 (55.24)
130 495 (26.81)
34 248 (7.04)
53 133 (10.91)

896 393 (62.12)
358 511 (24.85)
79 264 (5.49)
108 786 (7.54)

338 171 (69.47)
82 053 (16.86)
36 455 (7.49)
14 806 (3.04)
4 039 (0.83)
2 181 (0.45)
9 103 (1.87)

825 573 (57.21)
402 794 (27.91)
114 681 (7.95)
61 719 (4.28)
16 369 (1.13)
8 050 (0.56)
13 768 (0.95)

573 (0.12)
2 296 (0.47)
5 124 (1.05)
9 746 (2.00)
59 330 (12.19)
2 353 (0.48)
39 740 (8.16)
6 474 (1.33)

3 998 (0.28)
6 540 (0.45)
25 114 (1.74)
71 587 (4.96)
359 363 (24.90)
3 940 (0.27)
63 962 (4.43)
25 154 (1.74)

0.036
-0.003
0.059
0.162
0.332
-0.034
-0.154
0.034

10 311 (2.12)
13 775 (2.83)
93 180 (19.14)
111 443 (22.89)
78 359 (16.10)

28 316 (1.96)
60 506 (4.19)
243 557 (16.88)
345 828 (23.97)
255 535 (17.71)

-0.011
0.074
-0.060
0.025
0.043

0.046

-0.160

0.107

* As defined by Deyo et al. ** At least one prescription claim in baseline period, using GPI codes ***
Includes aspirin, antiplatelets, antithrombotics, and warfarin
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Table 3.5-Matched Cohort Baseline Characteristics

Female, n (%)
Age Categories, n (%)
30-39 y.o.
40-49 y.o.
50-59 y.o.
≥ 60 y.o.
Inpatient Visits, n (%)
0
1
>1
Outpatient Visits, n (%)
0-1
2-4
5-6
>6
CCI, n (%)*
0
1
2
3
4
5
≥6
Comorbidities, n (%)
AIDS
Ulcer
Congestive heart failure
Cerebrovascular disease
Diabetes
Liver disease
Cancer
Kidney disease
Medication Usage, n (%)**
Bisphosphonates
Blood thinners***
Corticosteroids
NSAIDs
PPIs

Active Comparator
n=1 442 954
722 274 (50.1)

Exposed
n=1 442 954
722 562 (50.1)

Standardized
Difference
0.000

106 958 (7.4)
342 710 (23.8)
643 926 (44.6)
349 341 (24.2)

108 560 (7.5)
345 783 (23.9)
642 956 (44.6)
345 636 (24.0)

0.004
0.005
-0.001
-0.006

951 277 (65.9)
327 073 (22.7)
164 585 (11.4)

947 452 (65.7)
328 118 (22.7)
167 365 (11.6)

-0.006
0.002
0.006

894 629 (62.0)
358 528 (24.9)
79 003 (5.5)
110 775 (7.7)

896 378 (62.1)
358 509 (24.9)
79 264 (5.5)
108 784 (7.5)

0.002
-0.000
0.001
-0.005

827 883 (57.4)
407 762 (28.3)
111 549 (7.7)
60 339 (4.2)
14 922 (1.0)
7 432 (0.5)
13 048 (0.9)

825 573 (57.2)
402 794 (27.9)
114 675 (8.0)
61 718 (4.3)
16 369 (1.1)
8 050 (0.6)
13 756 (0.9)

-0.003
-0.008
0.008
0.005
0.010
0.006
0.005

3 112 (0.2)
5 429 (0.4)
22 228 (1.5)
65 980 (4.6)
363 274 (25.2)
3 611 (0.3)
65 291 (4.5)
23 770 (1.7)

3 988 (0.3)
6 540 (0.5)
25 114 (1.7)
71 570 (4.9)
359 346 (24.9)
3 938 (0.3)
63 960 (4.4)
25 154 (1.7)

0.012
0.012
0.016
0.018
-0.006
0.004
0.004
0.007

28 164 (2.0)
61 032 (4.2)
242 186 (16.8)
345 256 (23.9)
258 341 (17.9)

28 314 (2.0)
60 505 (4.2)
243 552 (16.9)
345 816 (23.9)
255 529 (17.7)

0.001
-0.002
0.003
0.001
-0.005

* As defined by Deyo et al. ** At least one prescription claim in baseline period, using GPI codes ***
Includes aspirin, antiplatelets, antithrombotics, and warfarin
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Event Analysis
Amongst those who experienced the primary outcome (GIH), the average duration of
medication therapy for users was 505±448 days compared to 629±414 days for the active
comparator group. Statin users who experienced the primary outcome did so after an
average of 252±284 days of therapy, in comparison to 331±301 days of therapy for the
active comparator group.
The frequency of GIH in low, moderate, and high intensity statin users was
0.81±0.03%, 0.91±0.02%, and 0.90±0.05% respectively (two sample t-test p<0.002; see
Figure 3.3). For reference, a chart indicating which statin doses are included in each
intensity can be found in Appendix C.

Figure 3.3-Outcome Frequency by Statin Intensity

Comparing the rates of GIH between users and the active comparators, statin users
had 1.81 times the rate of GIH compared to the active comparator group (HR 1.81; 95%
CI 1.76-1.86; Table 3.6). Hazard ratios for secondary outcomes were not statistically
significant. Of note, the Cox Proportional Hazards model met all assumptions, but
because single subjects were used in multiple matched pairs, a robust variance estimator
was used. Using the incidence rate, the number of patients needed to be treated with a
statin to cause one GIH (number needed to harm; NNH) was 249. Using the cumulative
incidence, NNH for the primary outcome was 298.
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Table 3.6-Outcomes by Study Group
Outcome
GI Hemorrhage
GD Ulcer
Gastritis/Duodenitis

Active Comparators
No. of
Rate per 100
subjects
person-yr
8 009
0.490
2 749
0.167
17 832
1.10

Statin Users
No. of
Rate per 100
subjects
person-yr
12 866
0.891
2 802
0.193
19 713
1.37

Hazard
Ratio
1.81
1.13
1.19

95% CI
1.05
0.618
0.796

3.10
2.05
1.80

A time to event analysis is reflected in the Kaplan-Meier survival curve seen in
Figure 3.4. Amongst subjects who experienced GIH, 12.25% experienced it within one
month of therapy initiation, 54.89% within six months, 69.07% within 12 months, and
97.67% within three years. The maximum time to event amongst those who experienced
the outcome was four years and nine months.

Figure 3.4-Matched Cohort Kaplan Meier Survival Estimates
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SECTION FOUR: DISCUSSION
To our knowledge, this is the largest study that has investigated the association
between statin use and gastrointestinal bleeding events. The rigorous study design, along
with the robust analytic methods offer healthcare providers additional evidence to factor
into their decisions when prescribing statins to patients at a high risk of bleeding.
Because there have been other retrospective cohort studies that have investigated this
same question but have come to different conclusions, it is reasonable to discuss the
rationale behind the study design choices that may have influenced these results.

Study Design
Any study using retrospective data analysis must include in its design methods to
combat the inherent biases present. One of these biases occurs when comparing exposed
to unexposed individuals using users and non-users of the study drug. Non-users are
fundamentally different than users, predominantly in their health-seeking behaviors,
though also in other areas such as use of chronic and preventive medications. This study
utilizes an active comparator design, which is a well-validated method for reducing bias
in retrospective cohort studies. Schneeweiss and colleagues have shown that increasing
levels of restriction in observational studies brings study designs closer to that of a
randomized controlled trial (RCT).75 Based on a review of the literature, most studies
utilizing active comparator designs use either topical anti-glaucoma medications or
thyroid hormone substitution.58
The choice of following subjects for 90 days after treatment discontinuation was
based on the available evidence associating bleeding with statins. A plausible mechanism
may include clotting factor XIII inhibition, which has a half-life of 200 hours. Since on
average, it takes five half-lives for a substance to disappear, complete inhibition of factor
XIII would result in depletion after 41 days. Thus, it would be reasonable to conclude
that if a patient has not taken a statin for 41 days that any effect would start to diminish.
Increasing this interval to 90 days would allow for complete regeneration of factor XIII
back to baseline.
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Propensity Score Model
Another method this study used to reduce bias is propensity score matching (PSM).
The propensity score balances the distribution of baseline covariates between the exposed
and unexposed by estimating “the probability of treatment assignment conditional on
observed baseline characteristics.”76 However, the specification of the propensity score
model and the choice of algorithm used to match individuals are of utmost importance
and can significantly change results. For this reason, it is important that both choices are
thoughtfully made based on available literature.
Namely, the decision to match either with or without replacement is crucial to result
interpretation. When matching without replacement is performed, an unexposed case is
removed from the pool after it is used, which results in later matches having a larger
difference in propensity score (leading to greater bias in the model). In matching with
replacement, the closest unexposed individual is matched with an exposed individual,
allowing the unexposed case to be used multiple times if it is the best match for many
exposed cases. In the literature, matching with replacement is not commonly used. A
meta-analysis of propensity score-matched medical studies completed in 2007
demonstrated that approximately 30% of studies stated that matching without
replacement was used, but the rest did not state whether matching was done with or
without replacement.77 Dehejia and Wahba recommend that when the unexposed and
exposed groups are significantly different, or the unexposed group is small relative to the
exposed group, that matching with replacement results in better matches.74 Based on
these guidelines, this data is better suited to matching with replacement. Because the
same untreated subject can be used in multiple matched pairs, however, it does require
that the statistics account for this lack of independence in the pairs that have the same
untreated individual.77 For this reason, robust variance estimators were used to account
for clustering within matched pairs. Even so, there is a concern about bias if the active
comparator subjects selected to be matched are outliers and do not represent most
subjects. In this study, 21,552 active comparator subjects were matched to 1,442,954
exposed subjects (see Table 3.2). This can be alarming, but is reassuring to note that
nearly 90% of active comparator subjects were reused ≤ 60 times. Given that the exposed
group is composed of roughly 1.5 million subjects, this is not a large proportion. The
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maximum number of times one active comparator subject was reused to match an
exposed subject was 62,339.
Because matching with replacement is not commonly reported in the literature and
there are concerns of bias, the matching algorithm was run again without replacement to
ensure the best model was employed. It has been shown that matching without
replacement leads to more bias because the algorithm may be forced to use less optimal
matched pairs,74 but both models were run for completeness’ sake. As can be seen in
Table 3.3, the matched cohort designed without replacement had significantly more bias
than the one completed with replacement. A comparison of both models is discussed in
Appendix D. Importantly, both models reach the conclusion that there is a significant
association between statin use and gastrointestinal hemorrhage.
To determine whether the model accurately represents the data, we can view it both
graphically and statistically. Graphically, we can compare the distribution of propensity
scores in the exposed and active comparator groups. Because the propensity score is a
balancing score, we would want the two groups to be similar.
As can be seen in Figure 3.1, the propensity scores tend to be higher in the exposed
group than the active comparator group. This is expected: since these are the subjects
who were treated with statins, they have a higher probability of being treated. This
distribution also demonstrates the importance of performing a match with replacement.
As can be seen, there are significantly fewer active comparator subjects in the upper
range of the propensity scores. Matching without replacement would mean that once
these were used to match exposed subjects, later pairs would be worse matches.
To assess whether the algorithm resulted in “good” matches, it is possible to use a
variety of statistical measures. In the past, t-tests and p-values have been used, but simply
comparing means between variables isn’t very useful, since units may be different. Thus,
there has been a shift in the literature toward using the standardized mean difference
(SMD), which compares means in a unit-less way independent of sample size. The SMD
is also much less dependent on sample size, since it uses the standard deviation in its
calculation. A value of zero means that the two exposure groups have equivalent effects.
The values increase as the differences between exposed and active comparator groups
increase.78
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While there is no globally accepted method to interpret standardized difference, many
studies use an absolute value > 0.1 as the definition of imbalance between two groups.79
As seen in Table 3.4, the active comparator and exposed groups differ on nearly every
measured baseline characteristic in the unmatched cohort. However, the matched cohort
(seen in Table 3.5) has a much more even distribution between the exposure groups (no
standardized differences > 0.02). These findings suggest that the matching algorithm was
successful.

Event Analysis
The unmatched cohort’s baseline characteristics were unsurprising, in that the active
comparator group was generally healthier and younger than the user group. There was a
statistically significant difference between the two groups in sex and age, as well as in
diabetes and cancer incidence. However, the active comparator group was more similar to
the user group than a non-user group would have been. As an example, in a recent
propensity score-matched cohort study investigating the same matter, non-users differed
significantly on age, sex, inpatient and outpatient encounters, as well as in their
comorbidity scores.41 This difference demonstrates the power of an active comparator
group in removing unnecessary baseline bias between comparison groups.
After cohorts were matched using the propensity score, there were no statistically
significant differences between groups on baseline characteristics. However, it should be
noted that the user group duration of medication therapy was on average shorter than in
the active comparator group. This might be explained by the fact that in general, statin
users experience more adverse effects than thyroid hormone medication users which may
have caused earlier therapy termination.
Subjects who experienced a GIH were different in some ways than those who did not,
which is significant because initially both statin users and active comparators were well
matched. Predictably, there were more blood thinner and corticosteroid users in amongst
subjects who experienced the outcome, but there were also more PPI users. This is
interesting because in general, PPIs are thought to be protective of many types of GI
damage. This may be because those who experienced a GIH had first experienced an
ulcer and were put on a PPI as a result. In fact, 0.96% of subjects who experienced a GIH
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in the follow-up period previously had a gastroduodenal ulcer, compared to only 0.19%
of subjects who did not experience a GIH. The fact that these subjects previously had GI
damage may mean that they were at a higher risk, and may explain why more were taking
PPI therapy.
Another interesting difference is that those who experienced the primary outcome
used medication therapy for an average of approximately 8 months longer than those who
did not experience the primary outcome, but were also followed for a longer period of
time. This trend was consistent amongst statin users and active comparators. While this
information may make the association between treatment and outcome less clear, the time
to event analysis elucidates more details. The significant hazard ratio and the KaplanMeier survival curve demonstrate that at any particular time, 1.81 times as many subjects
in the statin user group experience an outcome compared to the active comparator group.
Over half of the subjects who did experience a GIH did so within six months of therapy
initiation, suggesting that there is also a time-related effect. When calculating the NNH,
using the incidence rate (which takes into account person-time) resulted in a lower
number than using the cumulative incidence (which does not take into account time).
This indicates that there is a temporal relation to the association between statin use and
GIH. Although ulcers, gastritis, and duodenitis did not have statistically significant
hazard ratios, the trend persisted even amongst these secondary outcomes. This time to
event analysis helps to remove some of the bias that is associated with having differing
follow-up times for each subject.
Looking at the difference in the primary outcome incidence amongst statin users,
there is no statistically significant difference between the moderate- and high-intensity
statin users, while low-intensity statin users have significantly fewer instances of the
primary outcome than both moderate- and high-intensity users. These results are in line
with previous in vitro studies that have found dose-dependent associations between
statins and bleeding events. This finding may call into question current prescribing
guidelines that recommend starting statin doses at the highest tolerable dose and adjusting
based on adverse effects, such as the 2013 ACC/AHA Guideline on the both primary and
secondary prevention of ASCVD.80 Conversely, the most recently released United States
Preventive Services Task Force (USPSTF) guidelines recommend initiating a low- or

26

moderate-intensity statin, suggesting that there is not sufficient evidence to determine
which statin dosing strategies are the most clinically effective.81 Given the ample
evidence linking higher dose statins to more adverse effects, the addition of the
information in this study would support starting at a lower statin intensity and titrating up
to effect.

Strengths and Weaknesses
As discussed, previous studies have attempted to demonstrate an association between
statin use and gastrointestinal bleeding events, but few have produced clinically
meaningful results. In early 2015, a retrospective propensity-score matched cohort study
investigated the possible association between upper GIH and statin use, finding neither an
increased nor decreased risk of GIH in statin users. Although the sample size was limited,
it was larger than any that had previously been studied to that point (6 342 statin users
matched 6 342 non-users).41 For this reason, it is reasonable to view the previously
mentioned study as a benchmark on which to improve, which this study has strived to
achieve.
Using propensity score matching to adjust for baseline differences in treatment
exposure and an active comparator design to reduce health-seeking behavior bias, this
study attempts to approximate a randomized controlled trial in design. The design of
propensity score model was done rigorously, and in line with current recommendations in
the literature. In contrast to other studies that include a wide variety of baseline covariates
to estimate propensity scores without justification (such as the 2015 Badillo study)41, this
study includes only true and potential confounders (covariates related only to the
outcome and those related both to exposure and outcome).
In addition, the study population represents a diverse group of individuals with claims
from nearly 350 payers throughout the United States. Censoring mechanisms were
chosen carefully to fulfill an analysis while treated instead of an intention to treat design.
Instead of following subjects until first event or disenrollment, as done in previous
studies, a censoring point 90 days after treatment discontinuation was chosen carefully
based on mechanistic hypotheses. Furthermore, a strong biological plausibility for an
association was established in this study through intensive background research.
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While every attempt was made to reduce bias and produce robustly accurate results,
certain limitations should be discussed. Foremost is the fact that propensity score
modeling is very much an art, as much as a science. Particularly, the choice of covariates
follow no rigorous guidelines, but rather are based on available literature in the field.
Thus, a different estimation of propensity scores may produce drastically different
results. While every attempt was made to create a model that considered all aspects that
may impact propensity for statin treatment, there is nevertheless room for variation.
Particularly, the PSM accounted for baseline use of blood thinners, which we defined as
receipt of a prescription for an anticoagulant, antiplatelet, antithrombotic, or aspirin in the
12-months prior to the index date. However, most patients do not use third-party claims
to pay for aspirin so its use would likely not appear in our model. Because statin users are
more likely use aspirin than thyroid hormone medication users (due to confounding
indications), there may be more statin users on blood thinners than accounted for in our
model.
Moreover, this study did not consider the effect of subjects re-initiating therapy at a
later date or switching therapy within the class. Subjects were considered as having
discontinued therapy if a gap of more than 90 days occurred in the prescription claim
database. Finally, it should be noted that the oldest subjects in this study were 65 years of
age at treatment initiation, with the average age of 52.8 years old. Because more patients
are being treated with statins for primary and secondary cardiovascular event prevention
at greater ages, this study may not represent a clinically relevant population.
In the future, studies may consider adding more elderly patients into the analysis to
make results more comparable to clinical prescribing habits. As an extension of this
study, a time-varying analysis may be undertaken to account for an individual subject
stopping and re-initiating therapy at a later date. It is clear from this data that many
subjects had gastrointestinal bleeding events after censoring due to treatment
discontinuation, and still more at multiple episodes of treatments with gaps interwoven.
Using a more sophisticated analysis may be able to take into account these higher level
usage patterns and more closely approximate a realistic hazard ratio.
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Conclusions
In comparing the frequency of events amongst statin users, both moderate and high
intensity statin users had higher a higher frequency of GIH than low intensity statin users.
However, this trend did not persist in the secondary outcomes, nor was there a
statistically significant difference in primary or secondary outcome frequency between
moderate and high intensity statin users. This finding suggests that GI bleeding adverse
effects may be associated with increased statin dosage, as has been suggested in the
literature.
This study is the largest known retrospective study investigating the association
between statin therapy and gastrointestinal hemorrhage. In a cohort of 2,885,870
propensity score-matched individuals aged 30-65 years, this study found that statin
therapy statistically significantly increased the rate of GIH by 81%. Clinically, this effect
size is surprising, but it should be noted that the benefits of statin therapy on
cardiovascular health continue to outweigh the risk of gastrointestinal bleeding events in
most patients.
In the paramount JUPITER study, the effect of statin therapy on the rate of
cardiovascular events was investigated.82 In this study, 17,802 healthy adults were
randomized to rosuvastatin 20 mg or a placebo. Investigators found that the rate of major
cardiovascular events was reduced by 43% in rosuvastatin users compared to the placebo
group (HR 0.56; 95% CI 0.46-0.69). This is quite significant clinically, and clinicians
would do well to note that based on the results of the JUPITER study, the number of
patients needed to treat with a statin to prevent one major cardiovascular event is merely
25. This is in comparison to the results of this study, which demonstrate that nearly 250
subjects need to be treated before one experiences a GIH. While these are stark
differences, it should be noted that JUPITER and this study are not directly comparable.
While this study considered all instances of GIH, JUPITER considered only “major”
instances. Presumably, if one were to restrict GIH events to only those that required
hospitalization the number needed to harm would become even more alarming.
Furthermore, only healthy patients were included in the JUPITER study, whereas this
study strove to include patients with a variety of comorbidities to more accurately
represent a clinically relevant population. When considering whether to prescribe a statin
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for cardiovascular protection, the risk of GIH is small for the general population and
statin benefits likely outweigh the risks.
In conclusion, this propensity score-matched cohort study demonstrated that a group
of statin users had significantly higher rates of gastrointestinal hemorrhage than a similar
group of thyroid hormone users. The results of this study may influence clinical decision
making in a select group of patients who are at a higher baseline risk of bleeding. In
patients who take anticoagulants or antiplatelets, or who have bleeding disorders, the risk
of cardiovascular events should be weighed carefully with the risk of GIH from statins.
While statins offer significant benefits in reducing cholesterol levels and cardiovascular
disease, this new insight may guide clinicians in making treatment decisions for patients
at higher baseline risks of bleeding.
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APPENDIX A : THYROID HORMONE AND GASTROINTESTINAL BLEEDING

Because this study employs a design with thyroid hormone users as the active
comparator, it was necessary to conduct a search of the literature to determine whether
there was any association between thyroid hormones and GI bleeding that could bias the
study. If there is some correlation between use of thyroid hormone and likelihood of GIH,
using these subjects as active comparators in a study investigating GIH may not be the
best method.
The thyroid gland is in the neck, just in front of the larynx. Its secreted hormone, T4,
is the precursor to T3, which modifies gene transcription and thus protein synthesis in
most tissues. Both T4 and T3 are well-known to affect nearly every organ and system in
the body.
The three major targets of thyroid hormone are the bone, the heart, and metabolism
regulation. Hypothyroidism has been associated with poor bone development in infancy,
whereas hyperthyroidism is associated with osteoporosis in adults (as T3 stimulates
osteocalcin).83,84 In the heart, hypothyroidism causes bradycardia as T3 stimulates cardiac
myocytes. In fact, thyroid hormones impact nearly every part of the cardiovascular
system including hypertension and various cardiovascular diseases.85 Both T3 and T4 can
“enhance cardiac function, promoting weight loss and reducing serum cholesterol.”86
Although this is a potential confounder with our statin users, excluding all statin users
who use thyroid hormones as well as thyroid hormone medication users who also use
statins will ideally eliminate this bias. The weight loss component of thyroid hormone is
due to its regulation of the metabolic rate, including its effects on glucose tolerance.87
Thyroid hormones also have an important role in hematology. Important effects include
stimulating red blood cell and hemoglobin production, so hypothyroidism can lead to
both micro- and macrocytic anemia,88 but other studies suggest that this isn’t a clinically
meaningful effect. However, a PubMed search for “thyroid AND bleed” provided only 19
results – none of which demonstrated a correlation between hyper- or hypothyroidism
and risk of hemorrhage.89
A PubMed search was also completed for “thyroid*[Title] AND
thrombocyto*[Title]” since thrombocytopenia is an important risk factor for GIH. Of the
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38 results, 11 pointed to an association between immune thrombocytopenia (ITP) and
auto-immune thyroid disease, such as Hashimoto’s disorder. However, this association
appears to be more related to an auto-immune disorder than the presence of hyper- or
hypothyroidism because ITP is also associated with other auto-immune disorders
unrelated to the thyroid gland.
Overall, while thyroid hormones are impactful on many body systems, it does not
appear that there is sufficient evidence to suggest any meaningful clinical correlation
between thyroid hormone substitution and GIH.
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APPENDIX B : ICD-9 DIAGNOSIS CODES

Comorbidity
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Rheumatic disease
Peptic ulcer disease
Mild liver disease
Diabetes without chronic complication
Diabetes with chronic complication
Hemiplegia or paraplegia
Renal disease
Any malignancy, except malignant
neoplasm of the skin
Moderate or severe liver disease
Metastatic solid tumor
AIDS/HIV

ICD-9 Code
410.x, 412.x
428.x
443.9, 441.x 785.4, V43.4, Procedure
38.48
430.x-438.x
290.x
490.x-505.x, 506.4
710.0, 710.1, 710.4, 714.0-714.2, 714.81,
725.x
531.x-534.x
571.2, 571.4-571.6
250.0-250.3, 250.7
250.4-250.6
344.1, 342.x
582.x, 583-583.7, 585.x, 586.x, 588.x
140.x-172.x, 174.x-195.8, 200.x-208.x
456.0-456.21, 572.2-572.8
196.x-199.1
042.x-044.x
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APPENDIX C : MEDICATIONS BY CLASS AND GPI CODES

Medication or Class
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Antiplatelet
Antipsychotic
Antithrombotic
Aspirin
Beta-blocker
Bisphosphonate
Calcium channel blocker
Corticosteroid
Diuretic
Hypoglycemic
Non-statin lipid lowering agent
Non-steroidal anti-inflammatory drug
Proton pump inhibitor
Sedative
Selective serotonin reuptake inhibitor
Statin
Testosterone
Thyroid hormone
Tricyclic antidepressant
Warfarin

GPI Code
3610x, 369915x, 369918x
3615x, 369945x, 369930x, 369940x,
369965x
8515x
59x
8560x
6410001x
33x, 369920x
300420x
34x, 369915x, 369945x, 369930x,
369968x
2210x
37x, 369920x, 369918x, 369945x,
369940x, 369968x, 369960x, 369990x
27997x, 2720x
3910x, 3930x, 3950x, 3999x
6610x
4927x, 499960x, 499930x
6010x, 6020x
5816x, 629950x
279930x, 3940x, 399940x, 409925x
2310x
281x, 9664508400, 9664584700,
9680569110
5820x, 6040x, 629920x, 629940x
8320003020

Statin Intensity Chart
High Intensity Statins
atorvastatin 40 – 80 mg
rosuvastatin 20 – 40 mg

Moderate Intensity Statins
atorvastatin 10 – 20 mg
rosuvastatin 5 – 10 mg
simvastatin 20 – 40 mg
pravastatin 40 – 80 mg
lovastatin 40 mg
fluvastatin 80 mg
pitavastatin 2 – 4 mg

* Adapted from Stone et al., 2013
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Low Intensity Statins
simvastatin 10 mg
pravastatin 10 – 20 mg
lovastatin 20 mg
fluvastatin 20 – 40 mg
pitavastatin 1 mg

APPENDIX D : PROPENSITY SCORE MODEL AND MATCHING
The following is the distribution of propensity scores in the complete, unmatched cohort:
Active Comparator
Exposed
Total

Mean
0.648
0.781
0.748

Std. Dev.
0.169
0.136
0.156

Minimum
0.051
0.044
0.044

Maximum
0.983
0.985
0.985

As shown, the region of common support (0.051 – 0.983) does not include all subjects, so
the common support restriction must be used.
We initially ran the one-to-one nearest neighbor propensity score matching algorithm
with replacement and without caliper and find that the maximum difference between
propensity scores in matched pairs is 0.150. The literature suggests it should be a
maximum of one-fourth the standard deviation of the propensity score in the unmatched
cohort.90 Thus, we will institute a caliper of 0.03989.
We run another one-to-one nearest neighbor propensity score matching algorithm with
replacement on the logit of the propensity score instituting the common support
requirement and a caliper of 0.03989. We exclude 19 exposed subjects who did not meet
the common support requirement. The results are as follows:
ATT
Unmatched
Matched

Exposed
0.00892
0.00892

Active Comparator
0.00802
0.00555

S.E.
0.000154
0.000993

Because we matched with replacement, 21 552 unexposed subjects were matched to 1
442 935 exposed subjects. This resulted in 8 009 unexposed subjects (0.56%) with a GIH
in the follow up period and 12 866 (0.89%) of the exposed subjects.
We also ran a one-to-one nearest neighbor propensity score matching algorithm without
replacement, instituting the same caliper as the previous model. However, this did not
result in a good match, as the average difference in propensity scores within a matched
pair was 0.0256, compared to the previous algorithm which was 0.000005. We instituted
a caliper of 0.001 with the following results:
ATT
Unmatched
Matched

Exposed
0.00892
0.00883

Active Comparator
0.00802
0.00826

S.E.
0.000154
0.000197

Because we matched without replacement and imposed a common support requirement,
only 436 067 exposed subject were matched to 436 067 unexposed subjects. This resulted
in 3 601 unexposed subjects (0.83%) with a GIH in the follow up period and 3 852
(0.88%) of the exposed subjects.

35

APPENDIX E : BASELINE CHARACTERISTICS BY OUTCOME GROUP

Female, n (%)
Age Categories, n (%)
30-39 y.o.
40-49 y.o.
50-59 y.o.
≥ 60 y.o.
Statin Intensity, n (%)
Low
Moderate
High
Inpatient Visits, n (%)
0
1
>1
Outpatient Visits, n (%)
0-1
2-4
5-6
>6
CCI, n (%)*
0
1
2
3
4
5
≥6
Comorbidities, n (%)
AIDS
Ulcer
Congestive heart failure
Cerebrovascular disease
Diabetes
Liver disease
Cancer
Kidney disease
Medication Usage, n (%)**
Bisphosphonates
Blood thinners***
Corticosteroids
NSAIDs
PPIs

No Outcome
n=2 864 995
1 435 196 (50.9)

Outcome
n = 20 875
9 640 (46.2)

Standardized
Difference
0.111

214 204 (7.5)
684 512 (23.9)
1 277 345 (44.6)
688 934 (24.05)

1 314 (6.3)
3 981 (19.1)
9 537 (45.7)
6 043 (28.95)

0.066
0.166
-0.031
-0.157

283 995 (9.9)
1 013 682 (35.4)
132 392 (4.6)

2 309 (11.1)
9 357 (44.8)
1 200 (5.8)

-0.053
-0.274
-0.072

1 886 689 (65.9)
649 261 (22.7)
329 045 (11.5)

12 040 (57.7)
5 930 (28.4)
2 905 (13.9)

0.239
-0.187
-0.103

1 780 836 (62.2)
711 333 (24.8)
156 937 (5.5)
215 889 (7.5)

10 171 (48.7)
5 704 (27.3)
1 330 (6.37)
3 670 (17.6)

0.386
-0.080
-0.054
-0.434

1 644 161 (57.4)
802 980 (28.0)
224 327 (7.8)
120 996 (4.20)
30 865 (1.1)
15 316 (0.5)
26 350 (0.9)

9 295 (44.5)
7 576 (36.3)
1 897 (9.1)
1 061 (5.1)
426 (2.0)
166 (0.8)
454 (2.17)

0.367
-0.251
-0.064
-0.058
-0.111
-0.045
-0.144

7 051 (0.3)
11 908 (0.4)
46 585 (1.6)
136 140 (4.8)
717 161 (25.0)
7 422 (0.3)
128 045 (4.5)
48 300 (1.7)

49 (0.2)
61 (0.3)
757 (3.6)
1 410 (6.8)
5 459 (26.2)
127 (0.6)
1 206 (5.8)
624 (3.0)

0.003
0.029
-0.177
-0.122
-0.036
-0.075
-0.084
-0.122

55 996 (2.0)
119 936 (4.2)
480 407 (16.8)
685 810 (23.9)
508 893 (17.8)

482 (2.3)
1 601 (7.7)
5 331 (25.5)
5 262 (25.2)
4 977 (23.8)

-0.035
-0.209
-0.305
-0.042
-0.212

* As defined by Deyo et al. ** At least one prescription claim in baseline period, using GPI codes ***
Includes aspirin, antiplatelets, antithrombotics, and warfarin

36

REFERENCES

1. Gu, Q., Paulose-Ram, R., Burt, V. & Kit, B. Prescription Cholesterol-lowering
Medication Use in Adults Aged 40 and Over: United States, 2003-2012. (National
Center for Health Statistics, 2014).
2. Aitken, M., Kleinrock, M., Lyle, J., Nass, D. & Caskey, L. Medicines Use and
Spending Shifts. (IMS Institute for Healthcare Informatics, 2015).
3. Lexicomp Online. Atorvastatin. (Wolters Kluwer Clinical Drug Information, 2015).
4. Mackman, N. The Role of Tissue Factor and Factor VIIa in Hemostasis. Anesth.
Analg. 108, 1447–1452 (2009).
5. Colli, S. et al. Vastatins Inhibit Tissue Factor in Cultured Human Macrophages A
Novel Mechanism of Protection Against Atherothrombosis. Arterioscler. Thromb.
Vasc. Biol. 17, 265–272 (1997).
6. Puccetti, L. et al. Role of platelets in tissue factor expression by monocytes in normal
and hypercholesterolemic subjects. In vitro effect of cerivastatin. Int. J. Clin. Lab.
Res. 30, 147–156 (2000).
7. Ferro, D., Basili, S., Alessandri, C., Cara, D. & Violi, F. Inhibition of tissue-factormediated thrombin generation by simvastatin. Atherosclerosis 149, 111–116 (2000).
8. Undas, A., Brummel, K. E., Musial, J., Mann, K. G. & Szczeklik, A. Simvastatin
depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor
XIII and by enhancing factor Va inactivation. Circulation 103, 2248–2253 (2001).
9. Dangas, G. et al. Pravastatin: An Antithrombotic Effect Independent of the
Cholesterol-lowering Effect. Thromb. Haemost. 688–692 (2016).
10. Zhao, Q. et al. Lovastatin induces platelet apoptosis. Environ. Toxicol. Pharmacol.
42, 69–75 (2016).
11. Pignatelli, P. et al. Rosuvastatin reduces platelet recruitment by inhibiting NADPH
oxidase activation. Biochem. Pharmacol. 84, 1635–1642 (2012).
12. Shen, L., Lu, G., Dong, N., Ma, Z. & Ruan, C. Simvastatin increases ADAMTS13
expression in podocytes. Thromb. Res. 132, 94–99 (2013).
13. Douketis, J. D., Melo, M., Bell, C. M. & Mamdani, M. M. Does statin therapy
decrease the risk for bleeding in patients who are receiving warfarin? Am. J. Med.
120, 369.e9-369.e14 (2007).
14. Atar, S. et al. Statins are associated with lower risk of gastrointestinal bleeding in
patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with
Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUSTIMI 16) trial. Am. Heart J. 151, 976.e1-6 (2006).
15. Tariq, M. et al. Gastric antisecretory and antiulcer effects of simvastatin in rats. J.
Gastroenterol. Hepatol. 22, 2316–2323 (2007).
16. Falcone, G. J. et al. Warfarin and statins are associated with hematoma volume in
primary infratentorial intracerebral hemorrhage. Neurocrit. Care 21, 192–199 (2014).
17. El-Hajj, I. I., Mourad, F. H., Shabb, N. S. & Barada, K. A. Atorvastatin-induced
severe gastric ulceration: A case report. World J. Gastroenterol. WJG 11, 3159–3160
(2005).
18. González-Ponte, M. L. et al. Atorvastatin-induced severe thrombocytopenia. Lancet
Lond. Engl. 352, 1284 (1998).

37

19. Groneberg, D. A., Barkhuizen, A. & Jeha, T. Simvastatin-induced thrombocytopenia.
Am. J. Hematol. 67, 277 (2001).
20. Possamai, G., Bovo, P. & Santonastaso, M. Thrombocytopenic purpura during
therapy with simvastatin. Haematologica 77, 357–358 (1992).
21. Vrettos, I. et al. Rosuvastatin-induced thrombocytopenia. South. Med. J. 103, 676–
678 (2010).
22. Yamada, T., Shinohara, K. & Katsuki, K. Severe Thrombocytopenia Caused by
Simvastatin in which Thrombocyte Recovery was Initiated after Severe Bacterial
Infection. Clin. Drug Investig. 16, 172–174 (1998).
23. Gurevich, A., Epstein, L. & Stein, G. Y. Generic atorvastatin-induced
thrombocytopenic purpura: a raised red flag. Isr. Med. Assoc. J. IMAJ 15, 197–198
(2013).
24. Koduri, P. R. Simvastatin and thrombotic thrombocytopenic purpura. Lancet Lond.
Engl. 352, 2020 (1998).
25. Sundram, F., Roberts, P., Kennedy, B. & Pavord, S. Thrombotic thrombocytopenic
purpura associated with statin treatment. Postgrad. Med. J. 80, 551–552 (2004).
26. Martinez-Suarez, H. J., Wang, R. & Faerber, G. J. Atorvastatin-induced hemorrhagic
cystitis: a case report. Urology 73, 681.e5-6 (2009).
27. Ames, P. R. J. Simvastatin-induced thrombocytopaenia: a further case and a brief on
its clinical relevance. Ann. Hematol. 87, 773–774 (2008).
28. Miserez, A. R., Rossi, F. A. & Keller, U. Prediction of the therapeutic response to
simvastatin by pretreatment lipid concentrations in 2082 subjects. Eur. J. Clin.
Pharmacol. 46, 107–114 (1993).
29. Nikolsky, E. et al. Impact of in-hospital acquired thrombocytopenia in patients
undergoing primary angioplasty for acute myocardial infarction. Am. J. Cardiol. 96,
474–481 (2005).
30. Özbakiş-Dengız, G., Hekımoğlu, A., Kandemır, N. & Kurcer, Z. Effects of statins in
an indomethacin-induced gastric injury model in rats. Turk. J. Gastroenterol. Off. J.
Turk. Soc. Gastroenterol. 23, 456–462 (2012).
31. Timoshin, S. S. et al. Effect of HMG-CoA-reductase inhibitor on DNA synthesis and
free radical oxidation in the gastric mucosa under normal conditions and during
indometacin-induced ulcerative process in the stomach of albino mice. Bull. Exp.
Biol. Med. 152, 298–300 (2012).
32. Huisa, B. N., Stemer, A. B. & Zivin, J. A. Atorvastatin in stroke: a review of
SPARCL and subgroup analysis. Vasc. Health Risk Manag. 6, 229 (2010).
33. Pandit, A. K. et al. High-dose statin therapy and risk of intracerebral hemorrhage: a
meta-analysis. Acta Neurol. Scand. (2015). doi:10.1111/ane.12540
34. Scheitz, J. F. et al. Dose-related effects of statins on symptomatic intracerebral
hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke J. Cereb.
Circ. 45, 509–514 (2014).
35. Schelleman, H. et al. Fibrate/Statin initiation in warfarin users and gastrointestinal
bleeding risk. Am. J. Med. 123, 151–157 (2010).
36. Woo, D. et al. Apolipoprotein E, statins, and risk of intracerebral hemorrhage. Stroke
J. Cereb. Circ. 44, 3013–3017 (2013).
37. Gulmez, S. E. et al. Do statins protect against upper gastrointestinal bleeding? Br. J.
Clin. Pharmacol. 67, 460–465 (2009).

38

38. Geng, J. et al. Early Use of Statin in Patients Treated with Alteplase for Acute
Ischemic Stroke. Acta Neurochir. Suppl. 121, 269–275 (2016).
39. McKinney, J. S. & Kostis, W. J. Statin therapy and the risk of intracerebral
hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke J. Cereb.
Circ. 43, 2149–2156 (2012).
40. van Rein, N. et al. Statins and Risk of Bleeding: An Analysis to Evaluate Possible
Bias Due to Prevalent Users and Healthy User Aspects. Am. J. Epidemiol. 183, 930–
936 (2016).
41. Badillo, R., Schmidt, R., Mortensen, E. M., Frei, C. R. & Mansi, I. Statin therapy and
gastrointestinal hemorrhage: a retrospective cohort study with propensity scorematching. Pharmacoepidemiol. Drug Saf. 24, 849–857 (2015).
42. Chung, P. & Kim, K. in Acute Gastrointestinal Bleeding: Diagnosis and Treatment
3–7 (Humana Press, 2003).
43. van Leerdam, M. E. Epidemiology of acute upper gastrointestinal bleeding. Best
Pract. Res. Clin. Gastroenterol. 22, 209–224 (2008).
44. Longstreth, G. F. Epidemiology and outcome of patients hospitalized with acute
lower gastrointestinal hemorrhage: a population-based study. Am. J. Gastroenterol.
92, 419–424 (1997).
45. Cryer, B. L. et al. The economics of upper gastrointestinal bleeding in a US
managed-care setting: a retrospective, claims-based analysis. J. Med. Econ. 13, 70–77
(2010).
46. Truven Health Analytics. Truven Health MarketScan(R) Research Databases. (2013).
47. Protection of Human Subjects. CFR 45, (2009).
48. SAS Institute Inc. SAS Enterprise Guide Software. (2014).
49. Deyo, R. A., Cherkin, D. C. & Ciol, M. A. Adapting a clinical comorbidity index for
use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45, 613–619
(1992).
50. Caliendo, M. & Kopeinig, S. Some Practical Guidance for the Implementation of
Propensity Score Matching. (Institute for the Study of Labor, 2005).
51. Brookhart, M. A. et al. Variable selection for propensity score models. Am. J.
Epidemiol. 163, 1149–1156 (2006).
52. Bryson, A., Dorsett, R. & Purdon, S. The Use of Propensity Score Matching in the
Evaluation of Labour Market Policies. (Department for Work and Pensions, 2002).
53. Rubin, D. & Thomas, N. Matching Using Estimated Propensity Scores: Relating
Theory to Practice. Biometrics 52, 249–64 (1996).
54. Heckman, J., Ichimura, H., Smith, J. & Todd, P. Characterizing Selection Bias Using
Experimental Data. Econometrica 66, 1017–1098 (1998).
55. Austin, P. C. Balance diagnostics for comparing the distribution of baseline
covariates between treatment groups in propensity-score matched samples. Stat. Med.
28, 3083–3107 (2009).
56. Kimura, A. & Iwamoto, T. [Acute massive gastrointestinal bleeding in the elderly].
Nihon Ronen Igakkai Zasshi Jpn. J. Geriatr. 46, 250–258 (2009).
57. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of
dementia. Cochrane Database Syst. Rev. CD003160 (2009).
doi:10.1002/14651858.CD003160.pub2

39

58. Solomon, D. H. et al. Cardiovascular outcomes in new users of coxibs and
nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk.
Arthritis Rheum. 54, 1378–1389 (2006).
59. Tandra, S. & Vuppalanchi, R. Use of statins in patients with liver disease. Curr.
Treat. Options Cardiovasc. Med. 11, 272–278 (2009).
60. Zhang, H., Plutzky, J., Shubina, M. & Turchin, A. Drivers of the Sex Disparity in
Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. PLOS
ONE 11, e0155228 (2016).
61. Boudreau, D. M., Yu, O. & Johnson, J. Statin use and cancer risk: a comprehensive
review. Expert Opin. Drug Saf. 9, 603–621 (2010).
62. Skrede, S., Tvete, I. F., Tanum, L., Steen, V. M. & Bramness, J. G. Incident users of
antipsychotic agents and future use of cholesterol-lowering drugs: an observational,
pharmacoepidemiologic study. J. Clin. Psychiatry 76, e111-116 (2015).
63. Dalal, J. J. et al. LIPITENSION: Interplay between dyslipidemia and hypertension.
Indian J. Endocrinol. Metab. 16, 240–245 (2012).
64. Rauchhaus, M. et al. The relationship between cholesterol and survival in patients
with chronic heart failure. J. Am. Coll. Cardiol. 42, 1933–1940 (2003).
65. Horwich, T. B., Hamilton, M. A., Maclellan, W. R. & Fonarow, G. C. Low serum
total cholesterol is associated with marked increase in mortality in advanced heart
failure. J. Card. Fail. 8, 216–224 (2002).
66. Di Napoli, M. Benefits of statins in cerebrovascular disease. Curr. Opin. Investig.
Drugs Lond. Engl. 2000 5, 295–305 (2004).
67. Ogata, T. et al. Gastrointestinal Bleeding in Acute Ischemic Stroke: Recent Trends
from the Fukuoka Stroke Registry. Cerebrovasc. Dis. Extra 4, 156–164 (2014).
68. Kalman, R. S. & Pedrosa, M. C. Evidence-based review of gastrointestinal bleeding
in the chronic kidney disease patient. Semin. Dial. 28, 68–74 (2015).
69. Acharya, T. et al. Statin Use and the Risk of Kidney Disease With Long-Term
Follow-Up (8.4-Year Study). Am. J. Cardiol. 117, 647–655 (2016).
70. Sarnak, M. J. et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice
Guideline for Lipid Management in CKD. Am. J. Kidney Dis. Off. J. Natl. Kidney
Found. 65, 354–366 (2015).
71. Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus
ezetimibe in patients with chronic kidney disease (Study of Heart and Renal
Protection): a randomised placebo-controlled trial. Lancet Lond. Engl. 377, 2181–
2192 (2011).
72. Peng, Y.-L. et al. Alendronate, a bisphosphonate, increased upper and lower
gastrointestinal bleeding: risk factor analysis from a nationwide population-based
study. Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl.
Osteoporos. Found. USA 25, 1617–1623 (2014).
73. Leuven, E. & Sianesi, B. PSMATCH2: Stata module to perform full Mahalanobis
and propensity score matching, common support graphing, and covariate imbalance
testing. (2003).
74. Dehejia, R. & Wahba, S. Propensity Score-Matching Methods for Nonexperimental
Causal Studies. Rev. Econ. Stat. 84, 161–61 (2002).

40

75. Schneeweiss, S. et al. Increasing Levels of Restriction in Pharmacoepidemiologic
Database Studies of Elderly and Comparison With Randomized Trial Results: Med.
Care 45, S131–S142 (2007).
76. Austin, P. C. An Introduction to Propensity Score Methods for Reducing the Effects
of Confounding in Observational Studies. Multivar. Behav. Res. 46, 399–424 (2011).
77. Austin, P. C. A critical appraisal of propensity-score matching in the medical
literature between 1996 and 2003. Stat. Med. 27, 2037–49 (2007).
78. Faraone, S. V. Interpreting Estimates of Treatment Effects. Pharm. Ther. 33, 700–
711 (2008).
79. Yang, D. & Dalton, J. A unified approach to measuring the effect size between two
groups using SAS. in 335–2012, (2012).
80. Stone, N. J. et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol
to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation 129, S1–S45 (2014).
81. Bibbins-Domingo, K. et al. Statin Use for the Primary Prevention of Cardiovascular
Disease in Adults: US Preventive Services Task Force Recommendation Statement.
JAMA 316, 1997–2007 (2016).
82. Ridker, P. M. et al. Rosuvastatin to Prevent Vascular Events in Men and Women
with Elevated C-Reactive Protein. N. Engl. J. Med. 359, 2195–2207 (2008).
83. Wojcicka, A., Bassett, J. H. D. & Williams, G. R. Mechanisms of action of thyroid
hormones in the skeleton. Biochim. Biophys. Acta 1830, 3979–3986 (2013).
84. Weiss, R. E. & Refetoff, S. Effect of thyroid hormone on growth. Lessons from the
syndrome of resistance to thyroid hormone. Endocrinol. Metab. Clin. North Am. 25,
719–730 (1996).
85. Grais, I. M. & Sowers, J. R. Thyroid and the heart. Am. J. Med. 127, 691–698 (2014).
86. Brenta, G., Danzi, S. & Klein, I. Potential therapeutic applications of thyroid
hormone analogs. Nat. Clin. Pract. Endocrinol. Metab. 3, 632–640 (2007).
87. Mullur, R., Liu, Y.-Y. & Brent, G. A. Thyroid hormone regulation of metabolism.
Physiol. Rev. 94, 355–382 (2014).
88. Dorgalaleh, A. et al. Effect of Thyroid Dysfunctions on Blood Cell Count and Red
Blood Cell Indice. Iran. J. Pediatr. Hematol. Oncol. 3, 73–77 (2013).
89. Iddah, M. A., Macharia, B. N., Ng’wena, A. G., Keter, A. & Ofulla, A. V. O.
Thryroid Hormones and Hematological Indices Levels in Thyroid Disorders Patients
at Moi Teaching and Referral Hospital, Western Kenya. ISRN Endocrinol. 2013,
(2013).
90. Austin, P. C. Optimal caliper widths for propensity-score matching when estimating
differences in means and differences in proportions in observational studies. Pharm.
Stat. 10, 150–161 (2011).

41

VITA
Ashley Martinez, PharmD/MS Candidate
EDUCATION AND TRAINING
University of Kentucky College of Pharmacy
Doctor of Pharmacy
Master of Science in Pharmaceutical Outcomes and Policy

Lexington, Kentucky
Expected May 2017

University of Chicago
Bachelor of Arts with Special Honors
Public Policy Analysis and Biological Sciences
Dean’s List: 2009-2013

Chicago, Illinois
June 2013

PROFESSIONAL LICENSURE AND CERTIFICATIONS
Pharmacist Intern License Number I11128
Kentucky Board of Pharmacy

2013 – Present

Pharmacy Technician License Number 049.175088
Illinois Department of Financial and Professional Regulation

2007 – Present

Certified Pharmacy Technician Number 550107010197399
Pharmacy Technician Certification Board

2010 – Present

Cardiopulmonary Resuscitation and Basic Life Support
First Response of the Bluegrass for Healthcare Providers

2013 – Present

Blood Borne Pathogens Safety Training
Occupational Health and Safety Department, University of Kentucky

2013 – Present

HIPAA Training Certified
Federal HIPAA Privacy Regulations

2007 – Present

Human Research Curriculum Certified
Collaborative Institutional Training Initiative

2010 – Present

PROFESSIONAL EXPERIENCE
Certified Pharmacy Technician
Walgreens Pharmacy

Lexington, Kentucky and Chicago, Illinois
August 2007 – Present

Pharmacist Intern
University of Kentucky Chandler Hospital

Lexington, Kentucky
April 2014 – December 2014

Teaching Assistant
University of Chicago, Department of Biological Sciences

Chicago, Illinois
September 2012 – June 2013

Research Assistant
Chicago Policy Research Team

Chicago, Illinois
January – June 2013

Research Assistant
University of Chicago Bernard-Mitchell Hospital, Hospitalist Project

Chicago, Illinois
September 2009-May 2011

42

PUBLICATIONS AND PRESENTATIONS
Martinez AI, Moga DC, Freeman PR. (2016) “Association of Gastrointestinal Effects and Statin Use: A Large
Propensity-Score Matched Retrospective Cohort Study” [Abstract]. Journal of the American Pharmacists Association.
56(3):e1-141
Martinez AI, Moga DC, Freeman PR. “Association of Gastrointestinal Effects and Statin Use: A Large Propensity
Score-Matched Retrospective Cohort Study.” Poster presented at: American Pharmacists Association Annual
Meeting and Exposition; 2016 March 4 – 7; Baltimore, Maryland.
Elliott C, Michnick AI. “Impact of Glycemic Control Clinical Education in a Rural Medical Center.” Poster
presented at: LifePoint Health Executive Patient Safety Conference; 2015 June 24 – 26; Nashville, Tennessee.
Michnick AI. “Effectively Using Primary Research to Decrease Hospital Medication Error.” Poster session
presented at: Kentucky Society of Health-System Pharmacists Spring Conference; 2014 May 9; Lexington,
Kentucky.
Michnick AI. (2014) Pharmacy Policy Issues: Effectively using pharmacists in interprofessional teams to reduce
hospital medication errors. The Kentucky Pharmacist. 9:38-9.
PROFESSIONAL ACTIVITIES
Chapter Leader, IHI Open School University of Kentucky Chapter
Pharmacy Student Representative, Patient Safety Student Interest Group
Committee Head, Public Policy, Kentucky Society of Health-System Pharmacists
Member, American Pharmacists Association—Academy of Student Pharmacists
Member, Kentucky Pharmacists Association
Member, National Community Pharmacists Association

April 2014 – May 2016
April 2013 – May 2016
March 2014 - 2015
August 2013 – Present
August 2013 – Present
August 2013 – Present

HONORS AND AWARDS
Dean’s List
University of Kentucky College of Pharmacy

May 2016

1st Place Poster Presentation, Pharmacy Student Division
Rho Chi Alpha Xi Chapter at the University of Kentucky College of Pharmacy
National Patient Counseling Competition Local Chapter Winner
American Pharmacists Association—Academy of Student Pharmacists

March 2016
February 2016

Wrightson Memorial Scholarship
University of Kentucky College of Pharmacy

2014 – 2017

Student Enhancement Scholarship
University of Kentucky College of Pharmacy

2013 – 2017

Thesis with Honors, Public Policy
The University of Chicago
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